ArticleFrontiers in oncology2026

Case Report: Use of mirvetuximab soravtansine in a patient with platinum-resistant ovarian cancer and concomitant PARP-inhibitor-related myelodysplastic syndrome.

Sophonie Shilonite Njonou Noujiep et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.